BYNDER
23.1.2024 13:45:26 CET | Business Wire | Press release
Bynder, a global leader in enterprise digital asset management (DAM) has today released data highlighting the strategic importance of enterprise DAM and content for brands looking to grow amidst market uncertainty and economic headwinds.
- Increased market demand highlighted by record number of new business logos and customer expansion in Q4 2023 as brands continue to see content as a strategic enabler
- AI functionality drives demand and is included in nearly 50% of new business deals in Q4
- Customers report time savings of 30-40% utilizing AI, and are 2x more likely to find the assets they need
- Leading indicators show significant growth in enterprise DAM usage and integration as businesses look to improve efficiency and drive increased ROI from their investments in content.
The need to deliver customers an exceptional content experience is driving more brands to look for efficiency, speed to value and increased ROI in the creation, management and distribution of content. In this landscape an enterprise DAM platform becomes mission critical as organizations compete for share of wallet in a growing and increasingly crowded digital and retail marketplace.
Recent AI innovations have highlighted Bynder’s market leadership, and its host of AI and automation capabilities have led to continued growth in new business, customer adoption and platform usage. The latest of these innovations, AI Search Experience, enables identification of similar assets and text in images, as well as the ability to search using images and identify duplicate assets. These capabilities allow teams to find, reuse and deliver more relevant content, quicker and more effectively.
Brittany Chase, Project Specialist at Architecture and Planning firm, HFA, said, “AI Search Experience would save between 30% and 40% of time from not having to upload and tag assets that already exist in the DAM.” In addition, a US-based healthcare company attributed a minimum saving of 6 hours a week to the new AI functionality, enabling team members to focus on more strategic initiatives.
As organizations continue to use content as a strategic advantage, usage of enterprise DAM enables efficiency across the entire content lifecycle. Across 2023, Bynder saw a 38% year-on-year growth in the number of assets stored on their platform, and a 250% increase in delivery of assets from Bynder’s platform to websites. Over the holiday season Bynder saw an exponential uplift in assets created, stored and distributed as brands looked to deliver exceptional digital shopping experiences.
Bynder’s hosts the largest marketplace of out of the box integrations and in 2023 this grew 38%. In addition, Bynder reported a 176% increase in API calls to their platform showing the criticality of a connected ecosystem to improve content operations.
Bynder CEO Bob Hickey said, “As digital commerce continues to accelerate, brands need to provide a seamless content experience to their customers. Our continued year-on-year growth, culminating in a record Q4 in 2023, indicates that investment in an enterprise DAM platform is vital for those looking to deliver content experiences while gaining compelling value and ROI from their content operations and IT investments.
“We’re pleased to see that our ongoing innovation and market leadership in AI has further driven our growth in Q4, highlighting that AI has become a strategic tool for marketers looking to streamline content operations and improve customer experience.”
For more information on Bynder and its AI capabilities, please visit https://www.bynder.com/en/solutions/initiatives/ai-automation/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240123344937/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
